Trials / Completed
CompletedNCT02487732
Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Korea University Anam Hospital · Academic / Other
- Sex
- All
- Age
- 30 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To investigate pleiotropic effects of ticagrelor in addition to its antiplatelet effects in type 2 diabetic patients with non-ST elevation acute coronary syndrome by measuring inflammatory markers, circulating number of endothelial progenitor cells, brachial artery endothelial function, and arterial stiffness.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ticagrelor | Ticagrelor 90mg twice daily for 5 weeks |
| DRUG | Prasugrel | Prasugrel 10mg once daily for 5 weeks |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2016-08-01
- Completion
- 2017-01-01
- First posted
- 2015-07-01
- Last updated
- 2019-04-25
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02487732. Inclusion in this directory is not an endorsement.